Humanized monoclonals and other biological initiatives

Clinical Biochemistry

Volumn 31, Issue 5, 1998, Pages 353-357

  Halloran, Philip F ^a   Prommool, Surazee ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD40 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; FAS LIGAND; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; HUMAN MONOCLONAL ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 4; LYMPHOCYTE ANTIBODY; LYMPHOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CELLULAR IMMUNITY; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0032128386     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00041-1     Document Type: Conference Paper

References (30)

1. Steiger J., Nickerson P.W., Steurer W., Moscovitch-Lopatin M., Strom T.B. IL-2 knockout recipient mice reject islet cell allografts. J Immunol. 155:1995;489-498.
2. + CTL response. J Exp Med. 183:1996;2129-2142.
3. Stout R.D., Suttles J., Xu J., Grewal I.S., Flavell R.A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol. 156:1996;8-11.
4. Grewal I.S., Xu J., Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature. 378:1995;617-620.
5. Elder M.E., Lin D., Clever J., et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science. 264:1994;1596-1599.
6. DiSanto J.P., Bonnefoy J.Y., Gauchat J.F., Fischer A., De Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature. 361:1993;541-543.
7. Korthäuer U., Graf D., Mages H.W., et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 361:1993;539-541.
8. Noguchi M., Yi H., Rosenblatt H.M., et al. Interleukin-2 receptor γ chain mutation results in x-linked severe combined immunodeficiency in humans. Cell. 73:1993;147-157.
9. Reith W., Satola S., Sanchez C.H., et al. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell. 53:1988;897-906.
10. Mach B., Steimle V., Reith W. MHC class II-deficient combined immunodeficiency a disease of gene regulation . Immunol Rev. 138:1994;207-221.
11. Giblett E.R., Anderson J.E., Cohen F., Meuwissen H.J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 2:1972;1067-1069.
12. Giblett E.R., Ammann A.J., Wara D.W., Sandman R., Diamond L.K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1975;1010.
13. Kawai K., Shahinian A., Mak T.W., Ohashi P.S. Skin allograft rejection in CD28-deficient mice. Transplantation. 61:1996;352-355.
14. Lucas P.J., Negishi I., Nakayama K.-I., Fields L.E., Loh D.Y. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol. 154:1995;5757-5768.
15. Chang C.-H., Guerder S., Hong S.-C., van Ewijk W., Flavell R.A. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity. 4:1996;167-178.
16. Zhang W., Zimmer G., Chen J., et al. T cell responses in calcineurin Aα-deficient mice. J Exp Med. 183:1996;413-420.
17. Batiuk T.D., Pazderka F., Halloran P.F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 59:1995;1400-1404.
18. Langman L.J., LeGatt D.F., Halloran P.F., Yatscoff R.W. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 62:1996;666-672.
19. Takada M., Chandraker A., Nadeau K.C., Sayegh M.H., Tilney N.L. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest. 100:1997;1199-1203.
20. Glotz D., Haymann J.P., Sansonetti N., et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation. 56:1993;335-337.
21. Wadström J., Gannedahl G., Bersztel A., Bengtsson M., Nättorp K., Mulec H. Successful kidney transplantation after suppression of HLA alloantibodies with intravenous immunoglobulin in a highly sensitized patient. Transplant Proc. 27:1995;3463-3464.
22. McIntyre J.A., Higgins N., Britton R., et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation. 62:1996;691-693.
23. Glotz D., Haymann J.P., Niaudet P., Lang P., Druet P., Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc. 27:1995;1038-1039.
24. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:1996;434-438.
25. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:1997;8789-8794.
26. Vincenti F., Kirkman R., Light S., et al. Anti-IL2R therapy with Daclizumab for prevention of acute renal rejection in renal transplantation. N Engl J Med. 338:1998;161-165.
27. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 350:1997;1193-1198.
28. Yamada K., Gianello P.R., Ierino F.L., et al. Role of the thymus in transplantation tolerance in miniature swine. I. Requirement of the thymus for rapid and stable induction of tolerance to class I-mismatched renal allografts. J Exp Med. 186:1997;497-506.
29. Wood K., Sachs D.H. Chimerism and transplantation tolerance cause and effect . Immunol Today. 17:1996;584-587.
30. Fechner J.H. Jr, Vargo D.J., Geissler E.K., et al. Split tolerance induced by immunotoxin in a rhesus kidney allograft model. Transplantation. 63:1997;1339-1345.